Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials

Detalles Bibliográficos
Autores principales: Dixit, Neal M., Amsterdam, Ezra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291608/
https://www.ncbi.nlm.nih.gov/pubmed/37378411
http://dx.doi.org/10.3389/fcvm.2023.1193226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291608/
https://www.ncbi.nlm.nih.gov/pubmed/37378411
http://dx.doi.org/10.3389/fcvm.2023.1193226

Ejemplares similares